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A 20-year-old nonverbal patient with profound developmental disabilities was treated with intravenous piperacillin-tazobactam
for respiratory infection. After 8 days, he became afebrile with normal pulmonary status, but his pulse remained inexplicably rapid
(114/minute). Investigations revealed severe normochromic normocytic hemolytic anemia (hemoglobin: 40g/L, reticulocytes:
9.4%, nucleated erythrocytes: 5%). While being hospitalized, patient experienced sudden cardiac arrest from which he was
successfully resuscitated. He had no blood loss or intrinsic heart disease to explain the acute anemia or cardiac arrest. He had
uneventfully received piperacillin-tazobactam on 7 occasions during the preceding 5 years for >50 days. Patient was treated
with intravenous crystalloids, methylprednisolone and transfusion of 3 units of packed erythrocytes. Piperacillin-tazobactam was
discontinued.AdirectantiglobulintestwaspositiveforimmunoglobulinGandcomplement.Antibodytopiperacillinwasdetected
in patient’s serum by the “immune-complex” method conﬁrming “piperacillin-induced immune hemolytic anemia (PIHA)”. On
discharge (day 15), patient’s hemoglobin improved to 115g/L (baseline: 131g/L). Vigilant clinical and hematological monitor-
ing for anemia is indicated in piperacillin-treated patients, particularly in those unable to verbalize their discomfort. Repeated
piperacillin exposure may sensitize and predispose patients to PIHA.
1.Introduction
Pulmonary and urinary infections are common causes of
morbidity and mortality. Piperacillin-tazobactam (Zosyn),
a synthetic penicillin-beta lactamase combination, is widely
used to treat these infections. Rarely, such treatment may
become complicated by the development of piperacillin-in-
duced immune hemolytic anemia (PIHA) [1–10]. Whereas
most aﬄicted patients help their physicians suspect PIHA
by reporting anemia symptoms, some not due to severe dis-
ability, serious illness, or medicine side eﬀects. Resultant
delay in treatment may be fatal. We report such an unusual
presentation of PIHA in a nonverbal patient where the only
clue to its diagnosis was an inexplicable tachycardia, later
complicated by cardiac arrest.
2. Case Presentation
Our patient lived in a facility for ∼400 people with severe
developmental disabilities. He was 20 years old, bedridden,
and unable to speak. He had a permanent tracheostomy and
feeding gastrostomy. He experienced frequent pulmonar-
y infections requiring intravenous antibiotics. Daily he re-
ceived 10mg montelukast and ipratropium-albuterol inhala-
tions for bronchospasm, 10mg hydrocortisone and 75mcg
levothyroxine for panhypopituitarism, 30mg levetiracetam
and 90mg phenobarbital for tonic clonic epilepsy, and 10mg
baclofen for spastic quadriplegia. His baseline hemoglobin
was 131g/L and core body temperature subnormal (36◦C).
On day 1 of this illness, patient developed fever (38.3◦C
or 101◦F), respiratory congestion, and leukocytosis. He
was treated with 3g piperacillin-375mg tazobactam (Zosyn
3.375g) intravenously every 6 hours. His pulmonary con-
dition gradually improved. On day 9, he had no fever, but
his pulse remained inexplicably rapid at 114 (usual: 80) per
minute. Testing revealed severe anemia (hemoglobin: 40g/L,
hematocrit:0.10,reticulocytes:9.4%,nucleatederythrocytes:
5%, hypochromasia, spherocytosis; Table 1). While being
hospitalized for this acute anemia, patient became pulseless2 Case Reports in Medicine
Table 1: Hematological parameters in the patient with severe piperacillin-induced immune hemolytic anemia.
Day Hematocrit
% Hemoglobin g/L Erythrocyte ×1012/L Leukocyte ×109/L Reticulocytes %
1 39.2 131 4.34 13.6 Normal
9 10.4 40 1.32 19.5 9.4
10 24.8 91 2.92 19 7.4
14 35.6 115 3.65 7.1 Normal
327 38.6 132 4.2 6.6 —
Normal 39–49 136–175 4.7–6.1 4.8–10.8 0.5–1.5
andapneic.Hewassuccessfullyresuscitatedfromthissudden
cardiacarrest.Patient’s subsequenttreatmentincludedintra-
venous crystalloids and methylprednisolone, transfusion of
three units of packed erythrocytes, and discontinuation of
piperacillin-tazobactam.
Investigations on day 9 revealed the following anomalies:
serum lactate dehydrogenase 412 (normal 88–230)u/L, se-
rum bilirubin 24 (normal <21)µmol/L, erythrocyte sedi-
mentation rate 140 (normal 1–10)mm/h, arterial blood car-
boxyhemoglobin 3.1 (normal: <9% of total hemoglobin, or
inthiscase0.36)g/dL,presenceofwarmantibodiesinserum,
and positive direct antiglobulin test for both immunoglobu-
lin G (IgG) and complement. Serum tests were negative for
immunoglobulin M antibody against cytomegalovirus, par-
vovirus and mycoplasma. Hemoglobinuria was absent indi-
cating that hemolysis was not intravascular. Serum collected
on day 15 was positive for antibody to piperacillin by the
“immune-complex” method, in which patient’s serum was
tested with erythrocytes in the presence of a solution of pipe-
racillin. Tracheal culture grew alkaligenes xylosoxidans (mu-
ltiple-antibiotic-resistant gram-negative bacilli) sensitive to
and uneventfully treated with tobramycin. Tracheal culture
was negative for inﬂuenza A and B, parainﬂuenza 1, 2, and 3,
andadenovirus.Ondischarge(day15),patient’shemoglobin
was 115g/L.
This patient had uneventfully received piperacillin-tazo-
bactam on 7 occasions during the preceding 5 years for a cu-
mulativetotalof>50days.Hehadnohistoryofheartdisease,
blood loss, hemolytic anemia, blood transfusion, Raynaud’s
disease, hepatosplenomegaly, systemic lupus erythematosus,
paroxysmal cold or nocturnal hemoglobinuria, or of treat-
ment with another hemolysis-associated drug.
3. Discussion
Was this patient’s severe anemia caused by piperacillin? We
used the Naranjo algorithm to address this critical issue [11].
The speciﬁc scores on the ten Naranjo questions were: Exis-
tence of previous conclusive reports of PIHA (score: 1), oc-
currence of anemia after piperacillin administration (score:
2), improvement upon piperacillin discontinuation (score:
1), no alternative cause for anemia (score: 2), no recurrence
of anemia with placebo (Score: 1), and objective conﬁrma-
tion of anemia (score: 1); answers to questions 4, 7, 8, and
9: no or not done (score: 0). The ﬁnal tally of 8 qualiﬁed
this patient’s anemia as a “probable” adverse drug reaction
to piperacillin. Piperacillin will not be administered to this
patient in the future.
Development of new anemia in patients treated with
multiple medicines should automatically arouse a suspicion
of an iatrogenic etiology. Of the ∼125 drugs inducing hemo-
lysis, the commoner ones are cefotetan, ceftriaxone, ticar-
cillin-clavulanate, ampicillin-sulbactam, levodopa, methyl-
dopa, and quinidine [12–16]. A handy clue to hemolysis in
nonsmokers is an elevated arterial blood carboxyhemoglo-
bin,atestcommonlyperformedoncriticallyillpatients[12].
Carbon monoxide is endogenously generated in equimolar
quantities during heme degradation, and its production
increases commensurate with hemolysis.
This patient had a positive direct antiglobulin test in-
dicating the presence of IgG autoantibodies and/or comple-
ment bound to the erythrocyte surface, and the diagnosis of
autoimmune hemolysis. With the knowledge of this patient’s
history, the probable cause of such hemolysis had to be a
drug, and piperacillin was the most likely culprit among the
active medicines in this case. Detection of piperacillin-anti-
body was conﬁrmatory; however, such testing is available
only in specialized centers [13].
“Warm antibodies” in the patient’s serum on day 9 pro-
bably were not autoantibodies because the patient never
had “idiopathic warm type autoimmune hemolytic anemia”
either before or after the current piperacillin episode. Those
warm antibodies were probably piperacillin (drug-depen-
dent)antibodiesthatwerereactingbecauseoftheinvivopre-
sence of piperacillin in the patient’s blood on day 9 [10, 12–
16]. Although a test for warm antibodies was not performed
in this case after discontinuation of piperacillin, such test
would probably have been negative due to subsequent loss of
piperacillin. Since warm antibodies hemolyze erythrocytes at
body temperature (≥37◦C), the anemia in PIHA is usually
severe, as in this patient. Piperacillin, like penicillin, acts as
a hapten to form stable piperacillin-erythrocyte membrane
complexes. Complement activation ampliﬁes the immune
reaction.
Piperacillin has been marketed since 1993, with $797
millioninsalesin2010.PIHAwasnotidentiﬁedduringpipe-
racillin’s clinical trials, but has been documented during its
postmarketing experience [17]. Precise incidence of PIHA is
not known, but PIHA is probably rare as only about 40 cases
(including two deaths) have been described in the literature
[1–10]. Nearly one-third of the PIHA cases, especially the
severe ones have occurred in patients with cystic ﬁbrosis,Case Reports in Medicine 3
a population prone to recurrent pulmonary infections just
liketracheostomypatients.Thelatencybetweenstartofpipe-
racillintreatmentanddiagnosisofPIHAhascommonlybeen
7–13 days. Both genders have been aﬀected equally, and the
patients’ ages have ranged between 23 and 68 years [1–10].
There are two striking similarities between our patient
and several published cases: prior piperacillin treatment on
multiple occasions and latency between piperacillin initiation
and development of anemia [1–10]. We hypothesize that
repeated piperacillin treatment may predispose to PIHA by
providing multiple opportunities for hapten-antigen challenge
and the activation of immune hemolysis. Perhaps repeated
piperacillin courses should be avoided, and piperacillin-treated
patients should be monitored with frequent blood counts.
Our patient had no prior heart disease, yet he experi-
enced sudden cardiac arrest—a near-fatal event. This was
obviously precipitated by the anemia-related severe myo-
cardial hypoxemia in a heart whose oxygen demand had in-
creased due to tachycardia. We credit our patient’s survival
to our facility’s heightened emphasis on clinical monitoring–
an astute employee’s attention to patient’s tachycardia was the
only clue to something being awry on day 9.
Our patient experienced a massive 70% reduction of his
hemoglobin within 8 days! Most patients with such seri-
ous illness would facilitate their diagnosis by reporting ane-
mia-related symptoms (asthenia, palpitation, dyspnea, chest
discomfort, or malaise). Our patient could not do so due to
his severe disability which in his case was preexisting! How-
ever, even many previously healthy patients may also become
unable to “partner” with their physicians due to mental ob-
tundation from serious illness or medicines. Thus, this case
alsohighlightstheneedforextremevigilancewhilecaringfor
individuals with severe disabilities or serious illnesses.
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